WallStSmart
INBS

Intelligent Bio Solutions Inc.

NASDAQ: INBS · HEALTHCARE · MEDICAL DEVICES

$4.11
-3.94% today

Updated 2026-06-03

Market cap
$6.77M
P/E ratio
P/S ratio
1.73x
EPS (TTM)
$-11.62
Dividend yield
52W range
$2 – $25
Volume
0.1M

Intelligent Bio Solutions Inc. (INBS) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-346.23%
Operating margin
-348.71%
ROE
-170.20%
ROA
-57.30%
Debt/equity
0.21x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2017$-340000.00
2018$-5.02M
2019$0.00$-7.34M
2020$188744.00$-3.71M100.00%-1,433.70%-1,967.77%
2021$1.98M$-7.04M100.00%-281.42%-355.33%
2022$0.00$-8.31M
2023$1.26M$-10.63M25.99%-1,002.11%-845.89%
2024$3.11M$-10.16M45.81%-330.46%-326.40%
2025$3.05M$-10.57M40.85%-348.71%-346.23%

Frequently asked questions

What is Intelligent Bio Solutions Inc.'s revenue?

Intelligent Bio Solutions Inc.'s trailing twelve-month revenue is $3.91M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is INBS?

In its most recent fiscal year, INBS ran a gross margin of 40.85%, an operating margin of -348.71%, and a net margin of -346.23%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does INBS generate?

INBS produced $-9.91M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is INBS's balance sheet healthy?

INBS holds $1.02M in cash and equivalents against — in long-term debt, on $3.00M of shareholder equity. That debt is best read against the cash flow the business throws off each year.